Posted by Michael Wonder on 27 Oct 2020
NICE publishes appraisal consultation document for avapritinib
27 October 2020 - Avapritinib is used to treat patients with an unresectable or metastatic gastro-intestinal stromal tumour.
Avapritinib is not recommended, within its marketing authorisation, for treating unresectable or metastatic gastro-intestinal stromal tumours that have the platelet derived growth factor receptor alpha (PDGFRA) D842V mutation in adults.
Avapritinib meets NICE’s criteria to be a life-extending treatment at the end of life. But, even taking that into account, the most plausible cost-effectiveness estimates are higher than the range normally considered a cost-effective use of NHS resources.
